Condition: Non-muscle Invasive Bladder Cancer · Sponsor: Pfizer
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will a…
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| The Kirklin Clinic of UAB Hospital | Birmingham, Alabama, United States | Recruiting |
| UAB Infusion Therapy Extended Care Clinic (ECC) | Birmingham, Alabama, United States | Recruiting |
| The University of Alabama at Birmingham Investigation Drug Services Pharmacy | Birmingham, Alabama, United States | Recruiting |
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Moffitt Cancer Center at SouthShore | Ruskin, Florida, United States | Recruiting |
| Moffitt Cancer Center - International Plaza | Tampa, Florida, United States | Recruiting |
| Moffitt Cancer Center - McKinley Campus | Tampa, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Moffitt McKinley Hospital | Tampa, Florida, United States | Recruiting |
| Moffitt Cancer Center at Wesley Chapel | Wesley Chapel, Florida, United States | Recruiting |
| Emory University Hospital Midtown | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07206225